Pilot Study Sample Clauses

Pilot Study. Since the intended audience of the study was teachers the surVey was piloted among six mathematics teachers to adapt it to the Kazakhstani context and to make sure that the translation of the instrument from English to Russian and Kazakh is accurate. It was important because the Views of the target audience on the questionnaire itself will finally exert influence on how they will be responding to the items (Xxxxx, 2004). The surVey was critiqued using a structured interView process, which has been described by Xxxxxx (2011) as an efficient method for piloting surVeys. Firstly, four mathematics teachers (2 Kazakh speaking teachers, and 2 Russian speaking teachers) reViewed the questionnaire for its Validity. The teachers during the pilot study were asked to xxXxxx the surVey and comment on the clarity of the questionnaire items, instructions, readability, and layout. Time taken to complete the surVey questionnaire was also recorded. The surVey was reVised based on the feedback and suggestions of the four reViewing teachers. The author of this study omitted the following item in the first part of the questionnaire: “If a student performs well in an actiVity and then fails to complete it, he does not haVe dyscalculia” because it was not clear to the teachers. Other changes were minor and concerned with the accurate translation of the items. In the end, the questionnaire was piloted with the remaining two mathematics teachers (Kazakh and Russian speaking). Both of them stated that all questions were clear and understandable in both languages (see Appendix C for detailed information about the changes in the items of the questionnaire). The population in this study was all primary and secondary mathematics teachers who work in urban mainstream schools in the selected city in Southern Kazakhstan. The site – a city in Southern Kazakhstan - is chosen for the current study due to its large economic releVance in Kazakhstan. GalimzhanoVa (2021) and ZhanatbekoVa (2018) haVe conducted research on teachers’ awareness of dyslexia and dyscalculia, respectiVely, in Northern Kazakhstan. The rationale behind choosing a city in Southern Kazakhstan as a research site is to extend the research on learning disabilities in this region. The participants were selected by the cluster sampling method as it allows selecting a specific number of schools and then surVeying all primary and secondary school mathematics teachers in those schools (Xxxxx et al., 2007). Special and selectiVe s...
Sample 1
AutoNDA by SimpleDocs
Pilot Study. After the Effective Date, TALi shall establish a plan for an initial clinical study for conduct of a pilot study for the RAG Offering (“Pilot Study Plan”) and submit such Pilot Study Plan for review and approval by the JSC. The JSC will use all reasonable endeavours to approve the Pilot Study Plan within [***] ([***]) days of its submission to the JSC, including holding additional meetings of the JSC for this purpose. Prior to accepting the Pilot Study Plan, the JSC may propose specific amendments to the Pilot Study Plan that TALi will use all reasonable endeavours to incorporate into any revised Pilot Study Plan that it may submit to the JSC in substitution for the previous Pilot Study Plan. Upon JSC approval of the Pilot Study Plan, TALi will conduct those activities assigned to it under the Pilot Study Plan in accordance with the timelines therein. Xxxxx will reimburse TALi for [***] percent ([***]%) of the direct out-of-pocket costs incurred by TALi for conducting the Pilot Study, excluding TALi internal costs, provided that such costs are reasonably documented and were incurred in accordance with the budget set forth in the Pilot Study Plan, and subject to the maximum Xxxxx reimbursement amount set forth in Section 4.4. Upon the conclusion of the Pilot Study, TALi will submit a report with all data and results from the Pilot Study in the form agreed upon in the Pilot Study Plan to the JSC (“Pilot Study Report”).
Sample 1
Pilot Study. After obtaining ethical approval both from my own university and the Turkish Ministry of National Education, during May 2010, several schools in Ankara, the capital of Turkey, were randomly identified via an Internet search. After making sure that the scientific inquiry learning approach was being used in these schools in accordance with the national curriculum, they were invited to participate in the pilot phase of this study, with the purpose of testing the feasibility of the initial research design as well as improving the quality and efficiency of the main study phase. After one of the public primary schools showed a willingness to participate, I sent the information sheet and consent forms to the science teacher of one class of sixth grade students (aged 12) and their parents for them to sign and return. Once this was obtained from all the participants, a meeting was arranged with the teacher and she was provided with more detailed information about the purpose of the pilot study as well as the data collection procedure. Also, she was asked to select two students to be focused upon during lesson observations based on their science achievement level (one high and one low-achieving) and anticipated willingness to share their thoughts with the researcher. Each of the chosen students was video recorded and observed during three of their science lessons. Moreover, field notes were taken during these lesson observations. While the initial design of this pilot phase also included conducting stimulated-recall and semi-structured interviews with the target students and teacher, owing to their full timetable, I was only able to carry out some informal interviews with the students during the break times concerning their perspectives on their engagement in science lessons. The observational video data was analysed in order to gain an insight into the students’ use of self-, co-, and shared regulation of their learning processes. In addition, the interview data and field notes were used to characterise the nature and context of the scientific inquiry activities observed. The pilot study phase was useful in helping me become more familiar with the research context and refining the data collection procedures for the main study phase. Moreover, its outcomes resulted in several important adjustments being made in relation to the initial research design. Firstly in this regard, it emerged that the students were engaging in both whole class and small group inquiry activ...
Sample 1
Pilot Study. Under the direction and supervision of Dr. Yuan Liu (the "Princxxxx Xxxxxxxgator"), Pilot Site shall use the System as described in the Protocol (hereinafter the "Protocol," which is attached hereto as Appendix 3) to test functionality, performance and reliability of the System (hereinafter referred to as the "Pilot Study"). Pilot Site shall conduct the Protocol in a manner that is consistent with the approved labeling, a copy of which is attached hereto as Appendix 1. Pilot Site shall consult with ABP and provide ABP with the full benefit of Pilot Site's knowledge, experience and skill in the field. Pilot Site represents that such Pilot Study shall be performed in a professional manner and according to the highest standards of the industry. Further, the responsibilities of both ABP and the Pilot Site in developing and implementing the Protocol are detailed in Section 5.
Sample 1
Pilot Study. On a monthly basis, measure and track “below target shifts” on each pilot unit. “Below target shifts” are identified as those shifts in which the actual numbers of RN hours are less than the number of RN hours that were scheduled for that shift by 8 or 12 hours, whichever is a “full shift” on that unit. Pilot units that report 15% or greater of shifts as “below target shifts” in their monthly report will be identified for immediate analysis and correction.
Sample 1
Pilot Study. The questionnaire for Round One of the Delphi survey was piloted with two children’s emergency nurses and two Paediatric Emergency Consultants to ensure that issues of validity and reliability were addressed prior to commencing the main study (Bowling 2014). Although the pilot study was optional (Xxxxx 1987), it proved useful in clarifying what was expected from participants prior to the main study. Following feedback from the pilot study, the proposed questions for Round One were modified (Table 3.2). Instead of requesting participants to ‘describe’ the activities and interventions of importance when caring for children in A&E Department, participants would be requested to ‘list’ activities and interventions, thus excluding the potential for ‘large and unwieldy amounts of information’ being produced (Xxxxxxx & Xxxx 1994, p.1004). Please describe the activities and interventions of importance that registered nurses should be able to do Please list the activities and interventions of importance that registered nurses should be able to do when caring for children in when caring for children in A&E Departments. A&E Departments.(maximum 15) Please describe what enables registered nurses to undertake these activities and interventions. Please list what enables registered nurses to undertake these activities and interventions. (maximum 7) Please describe what inhibits registered nurse from undertaking these activities and interventions. Please list what inhibits registered nurses from undertaking these activities and interventions (maximum 7)
Sample 1
Pilot Study. As presented in the summary on activity 2 the SW to be developed under a separate TA contract will be built up with the help of a modern SW development methodology. This methodology will include a cyclical process, under which the product is developed in iterations, i.e. in planned steps following pre-defined milestones. After each iteration the development team will carry out module tests and integration test, so that it is guaranteed that the system grows with a minimum of errors still existing in the product. From time to time acceptance tests will be performed, where the developers will present the functions of the current iteration. During these tests a current prototype of the system will be presented to the MoH and IHIS, or its representative and demanded functions will be tested against the specifications. This state-of-the-art process ensures that the design specifications are fulfilled during the creation of the SW , and most of the development errors will be detected and removed beforehand. As a consequence, the pilot study to be executed after finishing the SW development must not include large SW tests anymore. The essential task of the Pilot Study must be to test and evaluate the application of the SW in its daily working environment and to draw conclusions from it. It has to be tested whether the users are able to include the tasks connected with the new SW and whether they can be included in their daily work, or which measures need to be taken to render this possible. Expected measures are:
Sample 1
AutoNDA by SimpleDocs
Pilot Study. OCWD shall perform a PFAS treatment “Pilot Study” to evaluate different treatment technologies to remove PFAS from groundwater.
Sample 1
Pilot Study. A pilot study on 10 suspected pelvic tumor patients included in the study ،was done to explore the appropriateness of the study instruments and let the researcher training for data collection. The pilot study was improving study validity and reliability.
Sample 1

Related to Pilot Study

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Independent Study A sabbatical leave may be granted for a plan of independent study, research, writing, and/or travel equivalent in time and rigor to a sabbatical for formal study. A detailed, specific plan must be submitted by the applicant and approved by the Salary and Leaves Committee as likely to improve the applicant’s teaching effectiveness, strengthen the College’s academic program, or otherwise bring a clear benefit to students. In addition, sabbaticals for independent study must generate tangible products of use to students.

  • Feasibility Study A feasibility study will identify the potential costs, service quality and other benefits which would result from contracting out the work in question. The cost analysis for the feasibility study shall not include the Employer’s indirect overhead costs for existing salaries or wages and benefits for administrative staff or for rent, equipment, utilities, and materials, except to the extent that such costs are attributable solely to performing the services to be contracted out. Upon completion of the feasibility study, the Employer agrees to furnish the Union with a copy if the feasibility study, the bid from the Apparent Successful Bidder and all pertinent information upon which the Employer based its decision to contract out the work including, but not limited to, the total cost savings the Employer anticipates. The Employer shall not go forward with contracting out the work in question if more than sixty percent (60%) of any projected savings resulting from the contracting out are attributable to lower employee wage and benefit costs.

  • Development Work The Support Standards do not include development work either (i) on software not licensed from CentralSquare or (ii) development work for enhancements or features that are outside the documented functionality of the Solutions, except such work as may be specifically purchased and outlined in Exhibit 1. CentralSquare retains all Intellectual Property Rights in development work performed and Customer may request consulting and development work from CentralSquare as a separate billable service.

  • Development Phase contractual phase initiated with the approval of ANP for the Development Plan and which is extended during the Production Phase while investments in xxxxx, equipment, and facilities for the Production of Oil and Gas according to the Best Practices of the Oil Industry are required.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Concession Area, including its abandonment.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Development Program RWJPRI shall be [**] and have [**] in consultation with the JDAC, to select LICENSED COMPOUNDS which shall then be designated PRODUCTS for further DEVELOPMENT by RWJPRI and marketing by ORTHO and its AFFILIATES. RWJPRI shall provide KOSAN with written notice of its decision to select a LICENSED COMPOUND for DEVELOPMENT. Once a PRODUCT has been selected for further DEVELOPMENT, RWJPRI, with the advice of the JDAC, shall have the [**] right to develop the PRODUCT through STAGES O, I, II and III and shall have the [**] right to prepare and file, and shall be the owner of, all applications for MARKETING AUTHORIZATION throughout the world. During such DEVELOPMENT efforts, KOSAN will assist RWJPRI as may be mutually agreed, at RWJPRI's expense, in chemical development, formulation development, production of labeled material and production of sufficient quantities of material for STAGE O and initial STAGE I studies. RWJPRI shall exercise diligent efforts, commensurate with the efforts it would normally exercise for products with similar potential sales volume and consistent with its overall business strategy, in developing such PRODUCT in accordance with the DEVELOPMENT PLAN established by RWJPRI. In the course of such efforts RWJPRI shall, either directly or through an AFFILIATE or SUBLICENSEE to which the license shall have been extended, take appropriate steps including the following: (i) in consultation with the JDAC, select certain LICENSED COMPOUNDS for STAGE O DEVELOPMENT; and (ii) establish and maintain a program reasonably designed, funded and resourced to obtain information adequate to enable the preparation and filing with an appropriate and properly empowered national regulatory authority all necessary documentation, data and [**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. other evidence required for IND non-rejection to commence and conduct human clinical trials of such PRODUCT. (iii) proceed following IND non-rejection to commence PHASE I, II, and III clinical trials, associated studies and such other work which RWJPRI reasonably deems to be required for subsequent inclusion in filings for MARKETING AUTHORIZATION; (iv) after such submissions are filed prosecute such submissions and file all reasonably necessary, reports and respond to all reasonable requests from the pertinent regulatory, authorities for information, data, samples, tests and the like.

  • The Study 1The parties must comply with, and conduct the Study in accordance with, the Protocol and any conditions of the Reviewing HREC. In addition the parties must comply with the following, as applicable:

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!